Moleculin Biotech, Inc. (MBRX)
| Market Cap | 11.88M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -26.55M |
| Shares Out | 30.29M |
| EPS (ttm) | -3.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,738,322 |
| Open | 0.4000 |
| Previous Close | 0.3931 |
| Day's Range | 0.3750 - 0.4025 |
| 52-Week Range | 0.2500 - 3.6500 |
| Beta | 1.40 |
| Analysts | Strong Buy |
| Price Target | 5.00 (+1,174.21%) |
| Earnings Date | Aug 12, 2025 |
About MBRX
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for MBRX stock is "Strong Buy." The 12-month stock price target is $5.0, which is an increase of 1,174.21% from the latest price.
News
Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds
HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeti...
Moleculin Issues New Positive AML Overall Survival Data:
Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8) Median OS of 2 nd Line efficacy evaluable population of 12 months (n=9) Median OS of Intent to Treat population (1L...
Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
– Live video webcast on Wednesday, August 20 th at 2:00 PM ET HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceut...
Moleculin Reports Second Quarter 2025 Financial Results and Highlights
- Continues recruitment and opens US and EU sites for the Phase 2B/3 MIRACLE trial - 20+ additional clinical sites in Europe and the US expected to begin recruitment by the end of Q3
Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment
Presented data highlights the potential of Annamycin for treating broad range of human cancers, including high-need oncology indications
Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin
– New patent enhances market position in Europe HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company w...
Moleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference
– Video webcast now available on-demand HOUSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a b...
Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships
40+ year career at Roche founded on dedication to bringing new innovative medicines to patients and making them accessible
Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans
Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 MIRACLE trial
Moleculin Announces $5.9 Million Public Offering
HOUSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeti...
Moleculin Participates in Virtual Investor “What This Means” Segment
Watch the “What This Means" segment here
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML
Annamycin aims to eliminate cardiotoxicity associated with anthracyclines used to treat about 60% of all children with cancer FDA recommends inclusion of patients as young as 6 months – younger than ...
Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)
Access the on-demand webcast here HOUSTON, June 05, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad po...
Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)
Annamycin delivering better performance 7 th line than would be expected even in 2 nd line for monotherapy
Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Jenene Thomas - IR, JTC Team, LLC Walter Klemp - Founder, President, CEO and Chairm...
Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update
Enrollment and dosing underway in Phase 3 clinical trial (the “MIRACLE” trial) evaluating Annamycin (naxtarubicin) for the treatment of R/R AML
Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial
Adds nine additional countries to the Company's ongoing pivotal Phase 3 trial; Authorization granted in all EU countries requested
Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast
HOUSTON, May 07, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targetin...
Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin
Annamycin has the potential to be safer and more effective than current prescribed anthracyclines to treat serious, hard-to-treat cancers Ongoing pivotal, adaptive Phase 3 clinical trial (the “MIRACLE...
Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents
Company continues to expand global IP coverage and claims to major markets, now extending to June 2040 HOUSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” o...
Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Annamycin is potentially a highly versatile drug capable of working synergistically with numerous mechanistica...
Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
HOUSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates target...
Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial
– Initial data readout on track for second half of 2025 HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical ...
Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2024 Earnings Conference Call March 24, 2025 8:30 AM ET Company Participants Walter Klemp - Chairman and CEO John Paul Waymack - Senior CMO Jonathan Foster - ...
Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update
– Continued progress in pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) toward first subject treated, on track to take place in the first quarter of 2025